ECM biomarkers rise after treatment cessation

 

When should patients be dosed again? Increasing disease activity over time after dozing of Ocrelimuzab

After dosing, C4G, C4M, and PRO-C4 decrease. When patients are taken off treatment, all three biomarkers rise over weeks 21 to 61, indicating returning disease activity. This supports biomarker-guided re-dosing rather than fixed-interval protocols.